LIANHE TECHNOLOGY(SZ:002250)2022-12-08 03:10Group 1: Project Updates - The Yancheng Lianhua project received government approval for trial production in March 2015 and is currently in normal production and sales, generating expected benefits [1] - Other projects are actively seeking approval, but the timeline for trial production permits is uncertain [1] Group 2: Safety and Environmental Concerns - The company emphasizes the importance of safety in the production of phosgene, a toxic gas, and has heightened safety awareness following the Tianjin hazardous chemical explosion [1][2] - The company is committed to strict adherence to environmental laws and regulations, implementing proactive measures to reduce pollution and enhance environmental protection as a core competitive advantage [2][3] Group 3: Management and Talent Acquisition - The addition of Mr. Andreas, with experience in multinational companies, is expected to enhance the company's management in areas such as R&D, quality control, and supply chain management [2] - The company plans to recruit more international talent to further its globalization efforts [2] Group 4: Business Performance and Outlook - The pharmaceutical and intermediate business, while currently small, has a stable profit model and sufficient product pipeline for future revenue [2] - The company expects a net profit growth of 10%-30% for the first nine months of 2015 compared to the same period last year [3] - Currency fluctuations, particularly the depreciation of the RMB, are anticipated to have a positive impact on the company's performance due to its primary business being export-oriented [2]